REG - Oxford Biomedica PLC - Director Dealings <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

24/03/2016 13:44

RNS Number : 1708T
Oxford Biomedica PLC
24 March 2016
Director Dealings / Market Share Purchase
Oxford, UK - 24 March 2016:Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the Group, today acquired ordinary shares in the Group as set out below, under the market share purchase agreement outlined in the announcement on 15 December 2015 of his appointment.
 
Under the market share purchase agreement one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price. 
Interest after purchase
Director / PDMR
Title
Price per share (p)
Number of Ordinary Shares acquired
Number of Ordinary Shares
% of total
issued share capital
Dr Lorenzo Tallarigo
Chairman
6.35p
41,550
77,920
0.003%
The issued share capital of the Group is 2,702,853,244 ordinary 1p shares.
-Ends-
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes to editors
Oxford BioMedica
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of six gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSZMGZFLDKGVZG